Abstract
Autoimmune hepatitis (AIH) is a chronic progressive hepatitis, characterized by interface hepatitis with lymphoplasmacellular infiltrates on liver biopsy, high serum globulin level and circulating autoantibodies. It is classified into two types, according to autoantibody profile: type 1 is characterized by anti-nuclear (ANA) and/or anti-smooth muscle (SMA) antibodies; type 2 by anti-liver kidney microsomal type 1 (anti-LKM-1) antibodies. AIH affects all ages, may be asymptomatic, frequently has an acute onset, and can present as fulminant hepatitis. The diagnosis of AIH is based on a scoring system codified by an international consensus. Corticosteroids alone or in conjunction with azathioprine is the treatment of choice in patients with AIH and results in remission induction in over 80% of patients. Alternative proposed strategies in patients who have failed to achieve remission on standard therapy or patients with drug toxicity include the use of cyclosporine, tacrolimus, budesonide or mycophenolate mofetil. Liver transplantation is the treatment of choice in managing decompensated disease, however AIH can recur or develop de novo after liver transplantation.
Keywords: Autoimmune hepatitis, autoantibodies, autoimmune liver disease, immunosuppressive treatment
Mini-Reviews in Medicinal Chemistry
Title: Diagnosis and Therapy of Autoimmune Hepatitis
Volume: 9 Issue: 7
Author(s): Alessandro Granito, Paolo Muratori, Silvia Ferri, Georgios Pappas, Chiara Quarneti, Marco Lenzi, Francesco B. Bianchi and Luigi Muratori
Affiliation:
Keywords: Autoimmune hepatitis, autoantibodies, autoimmune liver disease, immunosuppressive treatment
Abstract: Autoimmune hepatitis (AIH) is a chronic progressive hepatitis, characterized by interface hepatitis with lymphoplasmacellular infiltrates on liver biopsy, high serum globulin level and circulating autoantibodies. It is classified into two types, according to autoantibody profile: type 1 is characterized by anti-nuclear (ANA) and/or anti-smooth muscle (SMA) antibodies; type 2 by anti-liver kidney microsomal type 1 (anti-LKM-1) antibodies. AIH affects all ages, may be asymptomatic, frequently has an acute onset, and can present as fulminant hepatitis. The diagnosis of AIH is based on a scoring system codified by an international consensus. Corticosteroids alone or in conjunction with azathioprine is the treatment of choice in patients with AIH and results in remission induction in over 80% of patients. Alternative proposed strategies in patients who have failed to achieve remission on standard therapy or patients with drug toxicity include the use of cyclosporine, tacrolimus, budesonide or mycophenolate mofetil. Liver transplantation is the treatment of choice in managing decompensated disease, however AIH can recur or develop de novo after liver transplantation.
Export Options
About this article
Cite this article as:
Granito Alessandro, Muratori Paolo, Ferri Silvia, Pappas Georgios, Quarneti Chiara, Lenzi Marco, Bianchi B. Francesco and Muratori Luigi, Diagnosis and Therapy of Autoimmune Hepatitis, Mini-Reviews in Medicinal Chemistry 2009; 9 (7) . https://dx.doi.org/10.2174/138955709788452676
DOI https://dx.doi.org/10.2174/138955709788452676 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Off-Label Use of Sunitinib in Patients with Advanced, Epithelial Thyroid Cancer: A Retrospective Analysis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry Fluoroquinolones: Blessings Or Curses
Current Drug Targets Uric Acid and the Kidney: Urate Transport, Stone Disease and Progressive Renal Failure
Current Pharmaceutical Design Late versus Early Onset Depression in Elderly Patients: Vascular Risk and Cognitive Impairment
Current Aging Science Early Brain Injury or Vasospasm? An Overview of Common Mechanisms
Current Drug Targets The Adaptive Value and Clinical Significance of Allostatic Blood Pressure Variation
Current Hypertension Reviews Editorial (Thematic Issue: From Gut Inflammation to Gastrointestinal Disorders Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities)
Current Pharmaceutical Design Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies
Current Pharmaceutical Biotechnology Nitric Oxide Donors as Potential Drugs for the Treatment of Vascular Diseases Due to Endothelium Dysfunction
Current Pharmaceutical Design Lung Structural Changes in Chronic Obstructive Pulmonary Diseases
Current Drug Targets - Inflammation & Allergy Bronchoalveolar Lavage in Systemic Sclerosis Patients: A Systematic Review
Current Rheumatology Reviews Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology Tissue Factor and Hypertension
Current Hypertension Reviews Methyl 2-Methoxycarbonyl-3-Phenylpropionate Derivatives: A New Type of Angiotensin Converting Enzyme Inhibitors
Letters in Organic Chemistry Combination Secondary Prevention Therapies in Vascular Diseases
Vascular Disease Prevention (Discontinued) Magnesium and Anaesthesia
Current Drug Targets Hypercortisolemia and Glucocorticoid Receptor-Signaling Insufficiency in Alzheimer’ s Disease Initiation and Development
Current Alzheimer Research Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design